Dayvigo vs Trazodone: Titration Speed and Tolerability Compared

What Is Lemborexant and How Is It Titrated?

Lemborexant blocks both OX1R and OX2R orexin receptors, reducing wake-promoting signals at sleep onset. The FDA approved it in December 2019 at two doses: 5 mg and 10 mg taken within 30 minutes of intended sleep. The prescribing label recommends starting at 5 mg and titrating to 10 mg only if the lower dose is tolerated but insufficiently effective 1.

Dose Steps and Timeline

The titration window is short. Because only two doses exist, a clinician can complete the titration decision within three to seven nights. Many patients notice sleep-onset improvement on night one at 5 mg, which means the decision to escalate is often clear within the first week.

Patients with moderate hepatic impairment must stay at 5 mg; the 10 mg dose is contraindicated in that population per the FDA label. Co-administration with strong CYP3A inhibitors such as clarithromycin also caps the dose at 5 mg 2.

SUNRISE-1 Efficacy Data

SUNRISE-1 was a phase 3, randomized, double-blind, placebo- and active-controlled trial (N=1,006) published in JAMA Network Open in 2019 1. At week 1, lemborexant 10 mg reduced subjective sleep-onset latency (sSOL) by 7.3 minutes versus placebo (P<0.001) and improved subjective wake after sleep onset (sWASO) by 19.0 minutes versus placebo. The 5 mg dose also outperformed placebo on both endpoints, though the effect size was smaller. The trial ran 12 months, and the efficacy signal held through month six and month 12 without tolerance development.

Next-Day Function

In SUNRISE-1, morning sleepiness as measured by the Karolinska Sleepiness Scale was not significantly different from placebo for the 5 mg arm at most timepoints. The 10 mg arm showed statistically higher sleepiness scores on some assessment days, but mean scores remained in the alert-to-slightly-sleepy range. Discontinuation due to somnolence was 3.4% for LEM 10 mg over 12 months 1.

What Is Trazodone and How Is It Titrated for Insomnia?

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) approved at higher doses (150 to 600 mg) for major depressive disorder, but prescribed widely at sub-antidepressant doses (25 to 150 mg) for insomnia. That insomnia use is entirely off-label 3.

Starting Dose and Ramp Protocol

Prescribers typically start at 25 to 50 mg at bedtime. The dose may increase by 25 to 50 mg increments every five to seven days based on response and tolerability, targeting 75 to 150 mg for sleep maintenance. Mendelson's 2005 review in the Journal of Clinical Psychiatry noted that the hypnotic effect is largely mediated by H1 histamine receptor antagonism and alpha-1 adrenergic blockade at low doses, not by serotonin reuptake inhibition 3.

The slower ramp is necessary because orthostatic hypotension and morning sedation occur more frequently during the first one to two weeks, before receptor downregulation partially attenuates those effects. Rushing to 100 mg in the first few nights increases the risk of falls in older adults 4.

Lack of FDA Approval and Prescribing Implications

Because trazodone carries no FDA insomnia indication, there is no manufacturer-defined titration schedule for sleep. Dosing guidance comes from expert consensus, pharmacokinetic principles, and individual trial data. The 2017 American Academy of Sleep Medicine (AASM) clinical practice guideline for chronic insomnia in adults gave trazodone a weak recommendation based on low-quality evidence, noting that "the overall quality of evidence was low due to imprecision and risk of bias" 5. Clinicians must weigh that context when selecting trazodone over an approved agent.

Head-to-Head Titration Speed

The titration arcs of these two drugs differ in both structure and required monitoring.

Lemborexant: Titration Complete in One Week

With lemborexant, titration is binary: 5 mg or 10 mg, decided within three to seven nights. There are no intermediate doses. A patient who tolerates 5 mg but still wakes frequently at 3 a.m. Simply steps up to 10 mg. No blood pressure checks, no orthostasis screening, no next-day driving assessment beyond the standard DORA counseling about morning drowsiness.

Trazodone: One to Two Weeks of Incremental Dosing

Trazodone titration takes longer because the therapeutic window for sleep (75 to 150 mg) sits close to the tolerability ceiling for next-day sedation in many patients. A typical protocol:

• Night 1 to 5: 25 to 50 mg
• Night 6 to 10: 50 to 75 mg (if tolerated)
• Night 11 to 14: 75 to 100 mg (target dose)

Each step requires at least three to five nights of observation. Patients who drive commercial vehicles or operate heavy machinery face meaningful functional impairment during the titration period.

Why Speed Matters Clinically

Faster titration reduces the cumulative nights of poor sleep a patient experiences before reaching a therapeutic dose. A 2021 systematic review in Sleep Medicine Reviews found that sleep debt accumulates measurably after even three to five nights of fragmented sleep, with next-day cognitive processing speed declining by roughly 20% 6. A drug that reaches target efficacy in one week rather than two may reduce that burden by half.

Tolerability Profiles Side by Side

The tolerability difference between lemborexant and trazodone is most visible in three domains: next-day sedation, cardiovascular effects, and special-population safety.

Next-Day Sedation

Both drugs can cause morning grogginess, but the mechanisms and magnitudes differ.

Lemborexant's half-life is 17 to 19 hours for the parent compound, which raises theoretical concern about accumulation. In practice, SUNRISE-1 found that next-morning alertness at 5 mg was statistically indistinguishable from placebo at most timepoints. A driving simulation sub-study (N=60) showed no significant impairment in standard deviation of lateral position (SDLP) the morning after a 5 mg dose; the 10 mg dose produced SDLP changes comparable to blood alcohol of approximately 0.05% 7.

Trazodone's sedating antihistamine and alpha-blocking activity persists six to eight hours post-dose in many patients. A 2016 crossover study (N=18) found that trazodone 100 mg produced significantly greater next-morning sedation on the Leeds Sleep Evaluation Questionnaire compared to zolpidem 10 mg (P<0.05) 8.

Cardiovascular and Orthostatic Effects

Trazodone's alpha-1 adrenergic blockade produces measurable orthostatic blood pressure drops, particularly during the first two weeks of use and in patients already taking antihypertensives. A retrospective cohort (N=2,314) found that trazodone users had a 1.4-fold increased risk of fall-related injury within 30 days of initiation compared to matched non-users 4. Priapism, though rare (estimated 1 in 6,000 male patients), is a serious adverse event unique to trazodone that warrants upfront counseling 3.

Lemborexant has no meaningful cardiovascular signal. SUNRISE-2 (N=949, 12-month) reported no clinically significant changes in heart rate or blood pressure versus placebo 9.

Older Adults

The 2023 American Geriatrics Society Beers Criteria does not list lemborexant as a drug to avoid in older adults, though it recommends starting at the lowest dose. Trazodone appears on the Beers list as a drug with potential for orthostatic hypotension and falls 10. For patients aged 65 and older, that distinction matters practically: a fall-related hip fracture in this population carries a one-year mortality of approximately 21% 11.

Pharmacokinetics and Mechanism: Why They Behave Differently

Understanding the pharmacology clarifies why titration speed and side-effect timing differ.

Lemborexant Mechanism

Lemborexant competitively and reversibly blocks OX1R and OX2R receptors. Orexin neuropeptides (orexin A and orexin B) promote wakefulness; blocking them tips the sleep-wake balance toward sleep without globally suppressing CNS activity. This receptor-specific mechanism avoids the broad antihistamine and anticholinergic receptor binding that drives hangover sedation in older hypnotics 1.

Oral bioavailability is approximately 87%. Time to maximum concentration (Tmax) is one to three hours. A high-fat meal delays Tmax by two hours without changing overall exposure, a point worth communicating to patients who take the drug after a large dinner.

Trazodone Mechanism at Hypnotic Doses

At 25 to 150 mg, trazodone's dominant receptor effects are H1 antagonism and alpha-1 blockade. SERT inhibition requires concentrations achieved at antidepressant doses (150 to 600 mg) and contributes minimally to the hypnotic effect at sleep doses. This pharmacological separation is why some patients with concurrent depression are prescribed both an SSRI for mood and low-dose trazodone for sleep, though additive serotonergic activity requires monitoring.

Trazodone's half-life is five to nine hours, shorter than lemborexant's parent compound. Yet the antihistamine hangover often persists well beyond what half-life calculations predict, possibly because H1 receptor occupancy remains high even at declining plasma concentrations.

Drug Interactions and Contraindications

Lemborexant Drug Interactions

CYP3A4 governs lemborexant metabolism. Strong CYP3A4 inhibitors (clarithromycin, itraconazole, ritonavir) can increase lemborexant exposure by three to four-fold, requiring dose reduction to 5 mg or avoidance. Moderate inhibitors (fluconazole, erythromycin) warrant caution. Strong CYP3A4 inducers such as rifampin reduce lemborexant exposure and may negate efficacy 2.

Concurrent CNS depressants, including opioids, benzodiazepines, and alcohol, carry additive respiratory depression risk. The FDA labeling carries a Boxed Warning for this combination.

Trazodone Drug Interactions

Trazodone is metabolized primarily by CYP3A4 and CYP2D6. Co-administration with strong CYP3A4 inhibitors raises trazodone plasma levels, increasing sedation and QTc prolongation risk. Trazodone prolongs the QTc interval modestly; combining it with other QTc-prolonging drugs (antipsychotics, certain antibiotics) requires an ECG baseline in higher-risk patients.

MAOIs are absolutely contraindicated with trazodone due to serotonin syndrome risk. A washout of at least 14 days between MAOI discontinuation and trazodone initiation is required.

Switching From Dayvigo to Trazodone (or Vice Versa)

Clinicians encounter switch scenarios in three common situations: formulary changes, side-effect intolerance, and inadequate efficacy.

Switching Dayvigo to Trazodone

No published pharmacokinetic data exists for an overlap transition between lemborexant and trazodone. Because the mechanisms do not share receptor targets (OX1R/OX2R vs. H1/alpha-1), simultaneous use for one to two nights during the cross-taper is theoretically possible with additive CNS depression as the primary risk.

A reasonable protocol: stop lemborexant on night one of trazodone initiation. Begin trazodone at 25 to 50 mg. Lemborexant will clear below therapeutic concentrations within two to three days given its 17 to 19-hour half-life. Do not start trazodone at the target dose of 100 mg on night one of the switch; the residual lemborexant plus full-dose trazodone may produce pronounced next-morning sedation.

Switching Trazodone to Dayvigo

This direction is simpler. Trazodone can be stopped without a taper when used solely at hypnotic doses (25 to 100 mg), because dependence and withdrawal are not established concerns at these doses. Start lemborexant at 5 mg on the first night trazodone is withheld. Reassess at one week.

Patients switching due to trazodone-related orthostasis or fall history should be counseled that lemborexant still carries a morning drowsiness risk, particularly at 10 mg, and driving the morning after initiation should be avoided until individual response is known 2.

When Trazodone Is Preferred Despite Slower Titration

Trazodone remains a reasonable choice when cost is the dominant factor. Generic trazodone costs approximately $10 to 20 per month at 100 mg; lemborexant 10 mg lists above $400 monthly without insurance. Trazodone may also suit patients with comorbid depression where sub-antidepressant doses are used as a bridge while an SSRI titrates, though this requires careful co-management. For patients who cannot tolerate Schedule IV medications due to regulatory or personal history concerns, trazodone's unscheduled status is an advantage.

Practical Prescribing Decision Framework

The choice often reduces to three questions.

1. How quickly does the patient need sleep improvement? Patients with severe occupational impairment from insomnia, or those who have already failed CBT-I, may benefit from lemborexant's faster titration arc. One week to target dose versus two weeks is a meaningful difference when a patient is missing work.

2. What is the cardiovascular and fall risk? Patients aged 65 or older, those on antihypertensives, or those with baseline orthostatic hypotension should strongly favor lemborexant. The Beers Criteria flag for trazodone is not academic: 21% one-year mortality after hip fracture in older adults is a real downstream risk 11.

3. What does the formulary allow? Many commercial plans require a prior authorization for lemborexant. Trazodone is almost universally covered. Prescribers initiating lemborexant should prepare a prior-auth citing SUNRISE-1 efficacy data and, where applicable, a documented trial and failure of at least one generic hypnotic.